tiprankstipranks
Arcus Biosciences price target raised to $46 from $38 at Citi
PremiumThe FlyArcus Biosciences price target raised to $46 from $38 at Citi
30d ago
Arcus: HIF-2a inhibitor, casdatifan data ‘shows promise’ in ccRCC treatment
Premium
The Fly
Arcus: HIF-2a inhibitor, casdatifan data ‘shows promise’ in ccRCC treatment
30d ago
Arcus Biosciences falls -9.3%
Premium
The Fly
Arcus Biosciences falls -9.3%
1M ago
Arcus Biosciences reports Q2 EPS ($1.02), consensus ($1.10)
PremiumThe FlyArcus Biosciences reports Q2 EPS ($1.02), consensus ($1.10)
4M ago
Sagimet Biosciences appoints Phillips, Jarrett to board of directors
Premium
The Fly
Sagimet Biosciences appoints Phillips, Jarrett to board of directors
4M ago
Arcus Biosciences price target lowered to $35 from $40 at Morgan Stanley
Premium
The Fly
Arcus Biosciences price target lowered to $35 from $40 at Morgan Stanley
4M ago
Roche failure likely worst case for Arcus study, says Cantor Fitzgerald
PremiumThe FlyRoche failure likely worst case for Arcus study, says Cantor Fitzgerald
5M ago
Arcus Biosciences price target lowered to $44 from $50 at Truist
Premium
The Fly
Arcus Biosciences price target lowered to $44 from $50 at Truist
5M ago
Arcus completes enrollment for domvanalimab study for GI cancer
Premium
The Fly
Arcus completes enrollment for domvanalimab study for GI cancer
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100